Figure 3
From: Primary cardiac tumors on the verge of oblivion: a European experience over 15 years
Survival in comparison to adjuvant treatment regimen matched population. Patients who were treated with adjuvant combination chemotherapy or doxorubicine and radiation had a statistically significant survival advantage (mean survival 45.7 ± 16.4 months) compared to patients who were treated with either radiation alone (4 months) or mono-chemotherapy (5 months) or who did not receive any adjuvant therapy. P < 0.05 by log rank.